Further investigation identified five of these candidates are significantly co-altered (LIMMA adjusted p < 0.05) at protein and transcript levels and exhibit concordant abundance trends, including EPPK1 and Pyrroline-5-carboxylate reductase (PYCRL) elevated in HRD vs HRP tumors and BMI1 Proto-Oncogene, Polycomb Ring Finger (BMI1), WD Repeat Domain 41 (WDR41), KH RNA Binding Domain Containing, Signal Transduction Associated 1 (KHDRBS1) reduced in HRD vs HRP tumors. This evidence concerns the gene RPRD1B and hypoparathyroidism-retardation-dysmorphism syndrome.